American association of clinical endocrinologists and associazione medici endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules

Endocrine Practice

Volumn 12, Issue 1, 2006, Pages 63-102

  Gharib, Hossein ^a,b   Papini, Enrico ^c,d   Valcavi, Roberto ^e   Baskin, Jack ^f   Crescenzi, Anna ^c   Dottorini, Massimo E ^g   Duick, Daniel S ^h   Guglielmi, Rinaldo ^c   Hamilton Jr , Carlos Robert ⁱ   Zeiger, Martha A ^j   Zini, Michele ^e  

^a Mayo Clinic   (United States)

^b American Association of Clinical Endocrinologists   (United States)

^c REGINA APOSTOLORUM HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e S MARIA NUOVA HOSPITAL   (Italy)

^f Florida Thyroid and Endocrine Clinic   (United States)

^g Ospedale di Cesena   (Italy)

^h Endocrinology Associates   (United States)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j DEPARTMENT OF PATHOLOGY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

THYROXINE;

ARTICLE; COMPARATIVE STUDY; CYTODIAGNOSIS; DIAGNOSTIC IMAGING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; METHODOLOGY; NEEDLE BIOPSY; PATHOLOGY; PRACTICE GUIDELINE; PROGNOSIS; RISK ASSESSMENT; STANDARD; THYROID FUNCTION TEST; THYROID NODULE; THYROID TUMOR; THYROIDECTOMY;

BIOPSY, FINE-NEEDLE; CYTODIAGNOSIS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; PROGNOSIS; RISK ASSESSMENT; THYROID FUNCTION TESTS; THYROID NEOPLASMS; THYROID NODULE; THYROIDECTOMY; THYROXINE;

EID: 77149130906     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.12.1.63     Document Type: Review

References (143)

1. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc. 1994;1:447-458.
2. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med. 1997;126:532-538.
3. American Association of Clinical Endocrinologists Ad Hoc Task Force for Standardized Production of Clinical Practice Guidelines. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10:353-361. (LOE 3 - guidelines)
4. Hegedus L. Clinical practice: the thyroid nodule. N Engl J Med. 2004;351:1764-1771. (LOE 4 - review)
5. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules: final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med. 1968;69:537-540. (LOE 3)
6. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226-231. (LOE 2)
7. Ezzat S, Sarti DA, Cain DR, Braunstein GD. Thyroid incidentalomas: prevalence by palpation and ultrasonography. Arch Intern Med. 1994;154:1838-1840. (LOE 2)
8. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1955;15:1270-1280. (LOE 3)
9. Ross DS. Diagnostic approach to and treatment of thyroid nodules. I. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate, 2005. (LOE 4)
10. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: advantages, limitations, and effect. Mayo Clin Proc. 1994;69:44-49. (LOE 4)
11. Belfiore A, Giuffrida D, La Rosa GL, et al. High frequency of cancer in cold thyroid nodules occurring at young age. Acta Endocrinol (Copenh). 1989;121:197-202. (LOE 3)
12. Loh KC. Familial nonmedullary thyroid carcinoma: a meta-review of case series. Thyroid. 1997;7:107-113. (LOE 2)
13. Hamburger JI, Husain M. Contribution of intraoperative pathology evaluation to surgical management of thyroid nodules. Endocrinol Metab Clin North Am. 1990;19:509-522. (LOE 4)
14. Papini E. The dilemma of non-palpable thyroid nodules. J Endocrinol Invest. 2003;26:3-4. (LOE 4 - editorial)
15. Kim WB, Han SM, Kim TY, et al. Ultrasonographic screening for detection of thyroid cancer in patients with Graves' disease. Clin Endocrinol (Oxf). 2004;60:719-725. (LOE 3)
16. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941-1946. (LOE 3)
17. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. Am J Med. 1992;93:363-369. (LOE 3)
18. Tan GH, Gharib H, Reading CC. Solitary thyroid nodule: comparison between palpation and ultrasonography. Arch Intern Med. 1995;155:2418-2423. (LOE 3)
19. Jarlov AE, Nygaard B, Hegedus L, Hartling SG, Hansen JM. Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid. 1998;8:393-398. (LOE 3)
20. Baskin HJ. Ultrasound of thyroid nodules. In: Baskin HJ, ed. Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy. Boston, MA: Kluwer Academic Publishers, 2000: 71-86. (LOE 4-review)
21. Mandel SJ. Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract. 2004;10:246-252. (LOE 4-review)
22. Cochand-Priollet B, Guillausseau PJ, Chagnon S, et al. The diagnostic value of fine-needle aspiration biopsy under ultrasonography in nonfunctional thyroid nodules: a prospective study comparing cytologic and histologic findings [erratum in Am J Med. 1994;97:311]. Am J Med. 1994;97:152-157. (LOE 3)
23. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid. 1998;8:989-995. (LOE 3)
24. Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab. 1999;84:24-28. (LOE 3)
25. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer. 1998;83:553-559. (LOE 3)
26. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery. 1992;112:1139-1146. (LOE 3)
27. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178:687-691. (LOE 2)
28. Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol. 2001;11:2411-2424. (LOE 4-review)
29. Pacella CM, Guglielmi R, Fabbrini R, et al. Papillary carcinoma in small hypoechoic thyroid nodules: predictive value of echo color Doppler evaluation; preliminary results. J Exp Clin Cancer Res. 1998;17:127-128. (LOE 3)
30. Castro MR, Gharib H. Thyroid fine-needle aspiration biopsy: progress, practice, and pitfalls. Endocr Pract. 2003;9:128-136. (LOE 4B)
31. Burch HB. Evaluation and management of the solid thyroid nodule. Endocrinol Metab Clin North Am. 1995;24:663-710. (LOE 4C)
32. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol. 1987;31:587-590. (LOE 3)
33. Gharib H, Goellner JR. Fine-needle aspiration biopsy of thyroid nodules. Endocr Pract. 1995;1:410-417. (LOE 4C)
34. Gharib H, Goellner JR, Zinsmeister AR, Grant CS, van Heerden JA. Fine-needle aspiration biopsy of the thyroid: the problem of suspicious cytologic findings. Ann Intern Med. 1984;101:25-28. (LOE 3)
35. Cersosimo E, Gharib H, Suman VJ, Goellner JR. " Suspicious" thyroid cytologic findings: outcome in patients without immediate surgical treatment. Mayo Clin Proc. 1993;68:343-348. (LOE 3)
36. Chow LS, Gharib H, Goellner JR, van Heerden JA. Nondiagnostic thyroid fine-needle aspiration cytology: management dilemmas. Thyroid. 2001;11:1147-1151. (LOE 3)
37. Gharib H, Goellner JR. Fine-needle aspiration biopsy of the thyroid: an appraisal. Ann Intern Med. 1993;118:282-289. (LOE 4B)
38. Caruso D, Mazzaferri EL. Fine needle aspiration biopsy in the management of thyroid nodules. Endocrinologist. 1991;1:194-202. (LOE 4C)
39. Jeffrey PB, Miller TR. Fine-needle aspiration cytology of the thyroid. Pathology (Phila). 1996;4:319-335. (LOE 4B)
40. Hamberger B, Gharib H, Melton LJ III, Goellner JR, Zinsmeister AR. Fine-needle aspiration biopsy of thyroid nodules: impact on thyroid practice and cost of care. Am J Med. 1982;73:381-384. (LOE 3)
41. Hamburger JI, Hamburger SW. Fine needle biopsy of thyroid nodules: avoiding the pitfalls. N Y State J Med. 1986;86:241-249. (LOE 4C)
42. McHenry CR, Slusarczyk SJ, Askari AT, et al. Refined use of scintigraphy in the evaluation of nodular thyroid disease. Surgery. 1998;124:656-661. (LOE 3)
43. Meier DA, Kaplan MM. Radioiodine uptake and thyroid scintiscanning. Endocrinol Metab Clin North Am. 2001;30:291-313, viii. (LOE 4 - review)
44. Bonnema SJ, Bennedbaek FN, Hegedus L. Danish endocrinologists' examination and treatment of non-toxic multinodular goiter: a questionnaire study [article in Danish]. Ugeskr Laeger. 2001;163:1265-1269. (LOE 3)
45. Hillenhinrichs H, Emrich D. Euthyroid goiter with and without functional autonomy in the euthyroid phase: a comparison [article in German]. Nuklearmedizin. 1998;37:95-100. (LOE 3)
46. Becker D, Bair HJ, Becker W, et al. Thyroid autonomy with color-coded image-directed Doppler sonography: internal hypervascularization for the recognition of autonomous adenomas. J Clin Ultrasound. 1997;25:63-69. (LOE 3)
47. Tollin SR, Fallon EF, Mikhail M, Goldstein H, Yung E. The utility of thyroid nuclear imaging and other studies in the detection and treatment of underlying thyroid abnormalities in patients with endogenous subclinical thyrotoxicosis. Clin Nucl Med. 2000;25:341-347. (LOE 3)
48. Meller J, Becker W. The continuing importance of thyroid scintigraphy in the era of high-resolution ultrasound. Eur J Nucl Med Mol Imaging. 2002;29(Suppl 2):S425-S438. (LOE 3)
49. Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab. 1990;70:453-460. (LOE 3)
50. Nicoloff JT, Spencer CA. Clinical review 12: the use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab. 1990;71:553-558. (LOE 4 - review)
51. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem. 1996;42:140-145. (LOE 4 - review)
52. Baloch Z, Carayon P, Conte-Devolx B, et al (Guidelines Committee, National Academy of Clinical Biochemistry). Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126. (LOE 3 - guidelines)
53. Ross DS. Laboratory assessment of thyroid dysfunction. In: Rose BD, ed. UpToDate. Wellesley, MA: UpToDate, 2005. (LOE 4 - review)
54. Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102-132. (LOE 4 - review)
55. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab. 1999;84:561-566. (LOE 3)
56. Date J, Feldt-Rasmussen U, Blichert-Toft M, Hegedus L, Graversen HP. Long-term observation of serum thyroglobulin after resection of nontoxic goiter and relation to ultrasonographically demonstrated relapse. World J Surg. 1996;20:351-356. (LOE 3)
57. Cohen R, Campos JM, Salaun C, et al (Groupe d'Etudes des Tumeurs a Calcitonine [GETC]). Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. J Clin Endocrinol Metab. 2000;85: 919-922. (LOE 3)
58. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1994;78:826-829. (LOE 3)
59. Thyroid Carcinoma Task Force. AACE/AAES medical/ surgical guidelines for clinical practice: management of thyroid carcinoma. Endocr Pract. 2001;7:202-220. (LOE 3 - guidelines)
60. Bennedbaek FN, Perrild H, Hegedus L. Diagnosis and treatment of the solitary thyroid nodule: results of a European survey. Clin Endocrinol (Oxf). 1999;50:357-363. (LOE 3)
61. Bennedbaek FN, Hegedus L. Management of the solitary thyroid nodule: results of a North American survey. J Clin Endocrinol Metab. 2000;85:2493-2498. (LOE 3)
62. Niccoli P, Wion-Barbot N, Caron P, et al (French Medullary Study Group). Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. J Clin Endocrinol Metab. 1997; 82:338-341. (LOE 3)
63. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89:163-168. (LOE 3)
64. Kotzmann H, Schmidt A, Scheuba C, et al. Basal calcitonin levels and the response to pentagastrin stimulation in patients after kidney transplantation or on chronic hemodialysis as indicators of medullary carcinoma. Thyroid. 1999;9:943-947. (LOE 3)
65. Erdogan MF, Gullu S, Baskal N, Uysal AR, Kamel N, Erdogan G. Omeprazole: calcitonin stimulation test for the diagnosis, follow-up and family screening in medullary thyroid carcinoma. J Clin Endocrinol Metab. 1997;82:897-899. (LOE 3)
66. Marsh DJ, Mulligan LM, Eng C. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Horm Res. 1997;47:168-178. (LOE 4 - review)
67. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671. (LOE 3 - guidelines)
68. British Thyroid Association. Guidelines for the management of thyroid cancer in adults. London: Royal College of Physicians of London and the British Thyroid Association, 2002. Available at: http://www.british-thyroid- association.org/complete%20guidelines.pdf. Accessed for verification December 1, 2005. (LOE 3 - guidelines)
69. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: thyroid carcinoma. Version 1. 2004. Available at: http:// www.mythyroid.com/documents/NCCN%20Thyroid%20Cancer%20Guidelines.pdf. Accessed for verification December 1, 2005. (LOE 3 - guidelines)
70. Mazzaferri E. Thyroid cancer: impact of therapeutic modalities on prognosis. In: Fagin JA, ed. Thyroid Cancer. Boston, MA: Kluwer Academic Publishers, 1998: 255-284. (LOE 4 - review)
71. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338:297-306. (LOE 4 - review)
72. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med. 1998;128:386-394. (LOE 3)
73. Papini E, Bacci V, Panunzi C, et al. A prospective randomized trial of levothyroxine suppressive therapy for solitary thyroid nodules. Clin Endocrinol (Oxf). 1993;38:507-513. (LOE 2)
74. Wemeau JL, Caron P, Schvartz C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab. 2002;87:4928-4934. (LOE 1)
75. Castro MR, Caraballo PJ, Morris JC. Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab. 2002;87:4154-4159. (LOE 1)
76. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for solitary thyroid nodules: a doubleblind controlled clinical study and cumulative meta-analyses. J Clin Endocrinol Metab. 1998;83:3881-3885. (LOE 1)
77. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study. N Engl J Med. 1987;317:70-75. (LOE 1)
78. Cheung PS, Lee JM, Boey JH. Thyroxine suppressive therapy of benign solitary thyroid nodules: a prospective randomized study. World J Surg. 1989;13:818-821. (LOE 2)
79. La Rosa GL, Ippolito AM, Lupo L, et al. Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab. 1996;81:4385-4387. (LOE 2)
80. Csako G, Byrd D, Wesley RA, et al. Assessing the effects of thyroid suppression on benign solitary thyroid nodules: a model for using quantitative research synthesis. Medicine (Baltimore). 2000;79:9-26. (LOE 2)
81. Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83: 780-783. (LOE 1)
82. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130: 350-356. (LOE 1)
83. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-4289. (LOE 1)
84. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331:1249-1252. (LOE 2)
85. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358: 861-865. (LOE 2)
86. Udelsman R, Westra WH, Donovan PI, Sohn TA, Cameron JL. Randomized prospective evaluation of frozen-section analysis for follicular neoplasms of the thyroid. Ann Surg. 2001;233:716-722. (LOE 3)
87. Segev DL, Umbricht C, Zeiger MA. Molecular pathogenesis of thyroid cancer. Surg Oncol. 2003;12:69-90. (LOE 4-review)
88. Moley JF, DeBenedetti MK. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg. 1999; 229:880-887. (LOE 3)
89. Lo Gerfo P. Local/regional anesthesia for thyroidectomy: evaluation as an outpatient procedure. Surgery. 1998;124: 975-978. (LOE 3)
90. Miccoli P, Berti P, Materazzi G, Minuto M, Barellini L. Minimally invasive video-assisted thyroidectomy: five years of experience. J Am Coll Surg. 2004;199:243-248. (LOE 3)
91. Livraghi T, Paracchi A, Ferrari C, et al. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: preliminary results; work in progress. Radiology. 1990;175:827-829. (LOE 3)
92. Papini E, Pacella CM, Verde G. Percutaneous ethanol injection (PEI): what is its role in the treatment of benign thyroid nodules? Thyroid. 1995;5:147-150. (LOE 4)
93. Papini E, Pacella CM. Percutaneous ethanol injection of benign thyroid nodules and cysts using ultrasound. In: Baskin HJ, ed. Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy. Boston, MA: Kluwer Academic Publishers, 2000: 169-213. (LOE 4-review)
94. Valcavi R, Frasoldati A. Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. Endocr Pract. 2004;10:269-275. (LOE 1)
95. Guglielmi R, Pacella CM, Bianchini A, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid. 2004;14:125-131. (LOE 3)
96. Verde G, Papini E, Pacella CM, et al. Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin Endocrinol (Oxf). 1994;41: 719-724. (LOE 1)
97. Kim JH, Lee HK, Lee JH, Ahn IM, Choi CG. Efficacy of sonographically guided percutaneous ethanol injection for treatment of thyroid cysts versus solid thyroid nodules. AJR Am J Roentgenol. 2003;180:1723-1726. (LOE 3)
98. Zingrillo M, Torlontano M, Chiarella R, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid. 1999;9: 763-767. (LOE 3)
99. Bennedbaek FN, Hegedus L. Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab. 2003;88:5773-5777. (LOE 1)
100. Monzani F, Lippi F, Goletti O, et al. Percutaneous aspiration and ethanol sclerotherapy for thyroid cysts. J Clin Endocrinol Metab. 1994;78:800-802. (LOE 3)
101. Monzani F, Goletti O, Caraccio N, et al. Percutaneous ethanol injection treatment of autonomous thyroid adenoma: hormonal and clinical evaluation. Clin Endocrinol (Oxf). 1992;36:491-497. (LOE 3)
102. Papini E, Panunzi C, Pacella CM, et al. Percutaneous ultrasound-guided ethanol injection: a new treatment of toxic autonomously functioning thyroid nodules? J Clin Endocrinol Metab. 1993;76:411-416. (LOE 3)
103. Lippi F, Manetti L, Rago T. Percutaneous ultrasoundguided ethanol injection for treatment of autonomous thyroid nodules: results of a multicentric study [abstract]. J Endocrinol Invest. 1994;17(Suppl 2 to no. 3):71. (LOE 3)
104. Livraghi T, Paracchi A, Ferrari C, Reschini E, Macchi RM, Bonifacino A. Treatment of autonomous thyroid nodules with percutaneous ethanol injection: 4-year experience. Radiology. 1994;190:529-533. (LOE 3)
105. Goletti O, Monzani F, Lenziardi M, et al. Cold thyroid nodules: a new application of percutaneous ethanol injection treatment. J Clin Ultrasound. 1994;22:175-178. (LOE 3)
106. Zingrillo M, Collura D, Ghiggi MR, Nirchio V, Trischitta V. Treatment of large cold benign thyroid nodules not eligible for surgery with percutaneous ethanol injection. J Clin Endocrinol Metab. 1998;83:3905-3907. (LOE 2)
107. Bennedbaek FN, Nielsen LK, Hegedus L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J Clin Endocrinol Metab. 1998;83:830-835. (LOE 1)
108. Zingrillo M, Modoni S, Conte M, Frusciante V, Trischitta V. Percutaneous ethanol injection plus radioiodine versus radioiodine alone in the treatment of large toxic thyroid nodules. J Nucl Med. 2003;44:207-210. (LOE 1)
109. Meier DA, Brill DR, Becker DV, et al (Society of Nuclear Medicine). Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002;43: 856-861. (LOE 3 - guidelines)
110. Dietlein M, Dressler J, Grunwald F, et al. Guideline for radioiodine therapy for benign thyroid diseases (version 3) [article in German]. Nuklearmedizin. 2004;43:217-220. (LOE 4-guidelines)
111. Moser E. Radioiodine treatment of Plummer's disease. Exp Clin Endocrinol Diabetes. 1998;106(Suppl 4):S63-S65. (LOE 4 - review)
112. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50:197-202. (LOE 3)
113. Holm LE, Hall P, Wiklund K, et al. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991;83:1072-1077. (LOE 3)
114. Ron E, Doody MM, Becker DV, et al (Cooperative Thyrotoxicosis Therapy Follow-Up Study Group). Cancer mortality following treatment for adult hyperthyroidism. JAMA. 1998;280:347-355. (LOE 3)
115. Mariotti S, Martino E, Francesconi M, et al. Serum thyroid autoantibodies as a risk factor for development of hypothyroidism after radioactive iodine therapy for single thyroid "hot" nodule. Acta Endocrinol (Copenh). 1986;113:500-507. (LOE 3)
116. Wallaschofski H, Muller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res. 2002;34:36-39. (LOE 3)
117. Lazarus JH. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond. 1995;29:464-469. (LOE 4 - guidelines)
118. Castro MR, Gharib H. Continuing controversies in the management of thyroid nodules. Ann Intern Med. 2005;142:926-931. (LOE 4)
119. Schlinkert RT, van Heerden JA, Goellner JR, et al. Factors that predict malignant thyroid lesions when fineneedle aspiration is "suspicious for follicular neoplasm." Mayo Clin Proc. 1997;72:913-916. (LOE 3)
120. McHenry CR, Walfish PG, Rosen IB. Non-diagnostic fine needle aspiration biopsy: a dilemma in management of nodular thyroid disease. Am Surg. 1993;59:415-419. (LOE 3)
121. Schmidt T, Riggs MW, Speights VO Jr. Significance of nondiagnostic fine-needle aspiration of the thyroid. South Med J. 1997;90:1183-1186. (LOE 3)
122. MacDonald L, Yazdi HM. Nondiagnostic fine needle aspiration biopsy of the thyroid gland: a diagnostic dilemma. Acta Cytol. 1996;40:423-428. (LOE 3)
123. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid. 1998;8:15-21. (LOE 3)
124. Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid. 1998;8:283-289. (LOE 3)
125. Kung AW, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002;87:1010-1014. (LOE 2)
126. Rosen IB, Korman M, Walfish PG. Thyroid nodular disease in pregnancy: current diagnosis and management. Clin Obstet Gynecol. 1997;40:81-89. (LOE 4)
127. Hegedus L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ. 1988;297:661-662. (LOE 3)
128. Nygaard B, Hegedus L, Gervil M, Hjalgrim H, Soe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ. 1993;307:828-832. (LOE 3)
129. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large compressive goiters treated with radioiodine. Ann Intern Med. 1994;121:757-762. (LOE 3)
130. de Klerk JM, van Isselt JW, van Dijk A, et al. Iodine-
131. therapy in sporadic nontoxic goiter. J Nucl Med. 1997;38:372-376. (LOE 3)
132. Silva MN, Rubio IG, Knobel M, et al. Treatment of multinodular goiters in elderly patients with therapeutic doses of radioiodine preceded by stimulation with human recombinant TSH. Endocr J. 2000;47(Suppl Aug):144. (LOE 3)
133. Duick DS, Baskin HJ. Utility of recombinant human thyrotropin for augmentation of radioiodine uptake and treatment of nontoxic and toxic multinodular goiters. Endocr Pract. 2003;9:204-209. (LOE 3)
134. Duick DS, Baskin HJ. Significance of radioiodine uptake at 72 hours versus 24 hours after pretreatment with recombinant human thyrotropin for enhancement of radioiodine therapy in patients with symptomatic nontoxic or toxic multinodular goiter. Endocr Pract. 2004;10:253-260. (LOE 3)
135. Albino CC, Mesa CO Jr, Olandoski M, et al. Recombinant human thyrotropin as adjuvant in the treatment of multinodular goiters with radioiodine. J Clin Endocrinol Metab. 2005;90:2775-2780. (LOE 3)
136. Pacella CM, Rossi Z, Bizzarri G, et al. Ultrasound-guided percutaneous laser ablation of liver tissue in a rabbit model. Eur Radiol. 1993;3:26-32. (LOE 3)
137. Pacella CM, Bizzarri G, Guglielmi R, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablation-a feasibility study. Radiology. 2000;217:673-677. (LOE 3)
138. Dossing H, Bennedbaek FN, Karstrup S, Hegedus L. Benign solitary solid cold thyroid nodules: US-guided interstitial laser photocoagulation- initial experience. Radiology. 2002;225:53-57. (LOE 2)
139. Papini E, Guglielmi R, Bizzarri G, Pacella CM. Ultrasound-guided laser thermal ablation for treatment of benign thyroid nodules. Endocr Pract. 2004;10:276-283. (LOE 3)
140. Miettinen M, Karkkainen P. Differential reactivity of HBME-1 and CD15 antibodies in benign and malignant thyroid tumours: preferential reactivity with malignant tumours. Virchows Arch. 1996;429:213-219. (LOE 3)
141. Bartolazzi A, Gasbarri A, Papotti M, et al (Thyroid Cancer Study Group). Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357:1644-1650. (LOE 3)
142. Segev DL, Clark DP, Zeiger MA, Umbricht C. Beyond the suspicious thyroid fine needle aspirate: a review. Acta Cytol. 2003;47:709-722. (LOE 4)
143. Cosgrove D. Future prospects for SonoVue and CPS. Eur Radiol. 2004;14(Suppl 8):116-124. (LOE 4)